133 related articles for article (PubMed ID: 28645838)
1. Sensitivity Analysis and Uncertainty Quantification in Pulmonary Drug Delivery of Orally Inhaled Pharmaceuticals.
Lu J; Xi J; Langenderfer JE
J Pharm Sci; 2017 Nov; 106(11):3303-3315. PubMed ID: 28645838
[TBL] [Abstract][Full Text] [Related]
2. Substance deposition assessment in obstructed pulmonary system through numerical characterization of airflow and inhaled particles attributes.
Lalas A; Nousias S; Kikidis D; Lalos A; Arvanitis G; Sougles C; Moustakas K; Votis K; Verbanck S; Usmani O; Tzovaras D
BMC Med Inform Decis Mak; 2017 Dec; 17(Suppl 3):173. PubMed ID: 29297393
[TBL] [Abstract][Full Text] [Related]
3. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
4. Quantification of particle deposition in asymmetrical tracheobronchial model geometry.
Farkas A; Balásházy I
Comput Biol Med; 2008 Apr; 38(4):508-18. PubMed ID: 18336809
[TBL] [Abstract][Full Text] [Related]
5. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals.
Nahar K; Gupta N; Gauvin R; Absar S; Patel B; Gupta V; Khademhosseini A; Ahsan F
Eur J Pharm Sci; 2013 Aug; 49(5):805-18. PubMed ID: 23797056
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary targeting of nanoparticle drug matrices.
Dandekar P; Venkataraman C; Mehra A
J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23(6):343-53. PubMed ID: 20455773
[TBL] [Abstract][Full Text] [Related]
7. Computational Models of Inhalation Therapy in Early Childhood: Therapeutic Aerosols in the Developing Acinus.
Katan JT; Hofemeier P; Sznitman J
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):288-98. PubMed ID: 26907858
[TBL] [Abstract][Full Text] [Related]
8. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
Wang YB; Watts AB; Peters JI; Williams RO
Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis.
Eriksson J; Sjögren E; Thörn H; Rubin K; Bäckman P; Lennernäs H
Eur J Pharm Biopharm; 2018 Mar; 124():1-12. PubMed ID: 29191716
[TBL] [Abstract][Full Text] [Related]
10. Impact of interpatient variability on organ dose estimates according to MIRD schema: Uncertainty and variance-based sensitivity analysis.
Zvereva A; Kamp F; Schlattl H; Zankl M; Parodi K
Med Phys; 2018 Jul; 45(7):3391-3403. PubMed ID: 29772064
[TBL] [Abstract][Full Text] [Related]
11. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
Farkas Á; Jókay Á; Balásházy I; Füri P; Müller V; Tomisa G; Horváth A
Eur J Pharm Sci; 2016 Oct; 93():371-9. PubMed ID: 27552906
[TBL] [Abstract][Full Text] [Related]
12. Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis.
Fenneteau F; Li J; Nekka F
J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):495-522. PubMed ID: 19847628
[TBL] [Abstract][Full Text] [Related]
13. Pediatric in vitro and in silico models of deposition via oral and nasal inhalation.
Carrigy NB; Ruzycki CA; Golshahi L; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):149-69. PubMed ID: 24870701
[TBL] [Abstract][Full Text] [Related]
14. Application of a One-Dimensional Computational Model for the Prediction of Deposition from a Dry Powder Inhaler.
Gourgoulianis K; Daniil Z; Athanasiou K; Rozou S; Bontozoglou V
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):435-443. PubMed ID: 28683222
[TBL] [Abstract][Full Text] [Related]
15. Characterization of regional and local deposition of inhaled aerosol drugs in the respiratory system by computational fluid and particle dynamics methods.
Farkas A; Balásházy I; Szocs K
J Aerosol Med; 2006; 19(3):329-43. PubMed ID: 17034308
[TBL] [Abstract][Full Text] [Related]
16. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
Rogueda PG; Traini D
Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
[TBL] [Abstract][Full Text] [Related]
17. Deposition of non-spherical particles in bifurcating airways.
Bunchatheeravate P; Curtis JS
Pharm Dev Technol; 2014 Dec; 19(8):942-51. PubMed ID: 24320756
[TBL] [Abstract][Full Text] [Related]
18. Influence of particle size on regional lung deposition--what evidence is there?
Carvalho TC; Peters JI; Williams RO
Int J Pharm; 2011 Mar; 406(1-2):1-10. PubMed ID: 21232585
[TBL] [Abstract][Full Text] [Related]
19. Assessment methods of inhaled aerosols: technical aspects and applications.
Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H
Expert Opin Drug Deliv; 2009 Sep; 6(9):941-59. PubMed ID: 19637979
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the primary particle size distributions of pressurized metered dose inhalers by using inkjet spray drying for targeting desired regions of the lungs.
Ehtezazi T; Davies MJ; Seton L; Morgan MN; Ross S; Martin GD; Hutchings IM
Drug Dev Ind Pharm; 2015 Feb; 41(2):279-91. PubMed ID: 24252108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
